Genomic testing for breast cancer in the neoadjuvant setting - European Medical Journal

Genomic testing for breast cancer in the neoadjuvant setting

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the value of genomic tests for identifying breast cancer patients who are likely to benefit from neoadjuvant chemotherapy. Genomic testing may be beneficial for patients with intermediate-risk factors, as determined by classic clinicopathological tools, of tumour progression during therapy.

This content is supported by Genomic Health, Inc.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.